{"disease":{"id":"copd","name":"Chronic Obstructive Pulmonary Disease (COPD)","therapeutic_area":"Respiratory","data":{"aiSummary":"The COPD treatment landscape is dominated by bronchodilators, including long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA), often used in combination. Inhaled corticosteroids (ICS) are added for patients with frequent exacerbations. Recent advances include triple therapy (ICS/LABA/LAMA) and novel inhaled PDE4 inhibitors. The pipeline includes new formulations and delivery devices, as well as novel targets like IL-33 and inhaled PDE3/4 inhibitors, aiming to improve lung function, reduce exacerbations, and enhance patient outcomes.","drug_count":7,"description":"Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease characterized by airflow obstruction, leading to difficulty breathing. It is primarily caused by long-term exposure to irritants, most commonly cigarette smoke. COPD encompasses chronic bronchitis and emphysema, resulting in inflammation, mucus production, and destruction of lung tissue, ultimately impairing gas exchange.","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.919Z","updated_at":"2026-03-25T12:16:34.919Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"tiotropium-bromide","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spiriva","generic_name":"TIOTROPIUM BROMIDE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":75,"revenue":"2500","mechanism":"Spiriva works by blocking the action of a chemical called acetylcholine, which causes airway muscles to contract and narrow the airways."},{"drug_id":"fluticasone-propionate","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"tiotropium","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TIOTROPIUM","company_name":"","drug_phase":"marketed","molecular_target":"M3 receptors, beta2-adrenoceptors","drug_class":"","quality_score":48,"revenue":null,"mechanism":"STIOLTO RESPIMAT combines tiotropium, an anticholinergic, and olodaterol, a beta-agonist, to achieve bronchodilation through different mechanisms."},{"drug_id":"roflumilast","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daliresp","generic_name":"ROFLUMILAST","company_name":"Arcutis","drug_phase":"marketed","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"Phosphodiesterase 4 Inhibitor [EPC]","quality_score":63,"revenue":null,"mechanism":"Daliresp works by blocking an enzyme called phosphodiesterase 4, which helps reduce inflammation in the body."},{"drug_id":"formoterol","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"formoterol","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foradil","generic_name":"FORMOTEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":56,"revenue":null,"mechanism":"Foradil works by stimulating the beta-2 adrenergic receptor to relax airway muscles and improve breathing."},{"drug_id":"fluticasone","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"indacaterol","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arcapta Neohaler","generic_name":"INDACATEROL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta2-Adrenergic Agonist","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABECOPD) caused by Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"ensifentrine","indication_name":"chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ohtuvayre","generic_name":"ENSIFENTRINE","company_name":"Verona Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Phosphodiesterase 3 Inhibitor [EPC]","quality_score":47,"revenue":null,"mechanism":"Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs."},{"drug_id":"flixotide","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"flixotide","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluticason","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"theophyllin","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Theophyllin","company_name":"University of Bergen","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"carbocysteine","indication_name":"Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mucodyne","generic_name":"carbocysteine","company_name":"","drug_phase":"marketed","molecular_target":"Mucus glycoprotein synthesis","drug_class":"Mucolytic","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"serevent","indication_name":"Bronchospasm Prevention with COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"serevent","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Serevent","company_name":"Fundacio Privada Mon Clinic Barcelona","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"daxas","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daxas","company_name":"AstraZeneca","drug_phase":"phase_2","molecular_target":"cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4D","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aminophyllin","indication_name":"COPD Associated with Chronic Bronchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Aminophyllin","company_name":"University of Padova","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"aclidinium-bromide","indication_name":"Maintenance treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tudorza Pressair","generic_name":"ACLIDINIUM BROMIDE","company_name":"Covis","drug_phase":"marketed","molecular_target":"M3 receptors, beta 2 -adrenergic receptors","drug_class":"Anticholinergic","quality_score":54,"revenue":null,"mechanism":"DUAKLIR PRESSAIR combines aclidinium, an anticholinergic, and formoterol, a beta 2 -adrenergic agonist, to provide bronchodilation in COPD."},{"drug_id":"salmeterol-xinafoate","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SALMETEROL XINAFOATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"budesonide-and-formoterol","indication_name":"Maintenance Treatment of COPD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"budesonide and formoterol","company_name":"National Jewish Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor, beta 2 -adrenoceptor","drug_class":"Corticosteroid [EPC]","quality_score":60,"revenue":null,"mechanism":"Budesonide reduces inflammation, while formoterol relaxes airway muscles, together improving symptoms of COPD and asthma."}],"pipeline":[{"drug_id":"scopolamine","indication_name":"Chronic obstructive pulmonary disease (COPD)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SCOPOLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Anticholinergic [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":27,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04905420","title":"The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap Patients","phase":"","overall_status":"COMPLETED","enrollment_count":288538,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03381573","title":"Long-term Observational Study of the Safety of Roflumilast","phase":"","overall_status":"COMPLETED","enrollment_count":135856,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05825014","title":"Predicting Adverse Outcomes Using Machine Learning of COPD Patients in Hong Kong","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07436104","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":72564,"lead_sponsor_name":"MAHAN Trust","has_results":false},{"nct_id":"NCT04192175","title":"Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning","phase":"","overall_status":"COMPLETED","enrollment_count":65000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04966637","title":"Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data","phase":"","overall_status":"COMPLETED","enrollment_count":54028,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT04138758","title":"Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS","phase":"","overall_status":"COMPLETED","enrollment_count":42953,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04684836","title":"Comparative Effectiveness of Telemedicine in Primary Care","phase":"","overall_status":"COMPLETED","enrollment_count":33100,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT07532564","title":"Risk Factors, Costs, and Impacts of ED Boarding","phase":"","overall_status":"COMPLETED","enrollment_count":30486,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT06512142","title":"Using Artificial Intelligence for the Detection of Respiratory Diseases Associated With Pollution","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"University of Medicine and Pharmacy \"Victor Babes\" Timisoara","has_results":false},{"nct_id":"NCT07332156","title":"Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas","phase":"","overall_status":"COMPLETED","enrollment_count":21692,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05062304","title":"Replication of the IMPACT COPD Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":17281,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02760329","title":"Observational Study of Obstructive Lung Disease (NOVELTY)","phase":"","overall_status":"COMPLETED","enrollment_count":12255,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06685315","title":"Research on the Characteristics of Chronic Airway Diseases (asthma, COPD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10545,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT03532893","title":"Predictive Value of Inflammatory Biomarkers and FEV1 for COPD","phase":"","overall_status":"COMPLETED","enrollment_count":10385,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT03359122","title":"Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD Patients","phase":"","overall_status":"COMPLETED","enrollment_count":10067,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05563675","title":"Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10011,"lead_sponsor_name":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","has_results":false},{"nct_id":"NCT06577701","title":"Respiratory Disease Cohort Studies of Chinese Medicine for COPD(RESEARCH-COPD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT07382986","title":"IMPACT COPD Cohort (China)","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Beijing Chao Yang Hospital","has_results":false},{"nct_id":"NCT06652776","title":"The Italian Registry of Patients with Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of Milan","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT05952999","title":"Analysis of the Virtual Acute Care at Home Experience","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":9654,"lead_sponsor_name":"OSF Healthcare System","has_results":false},{"nct_id":"NCT05315908","title":"COVID-19 Testing in Underserved and Vulnerable Populations","phase":"NA","overall_status":"TERMINATED","enrollment_count":9120,"lead_sponsor_name":"Jesse Nodora","has_results":true},{"nct_id":"NCT02465567","title":"Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8588,"lead_sponsor_name":"Pearl Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05766046","title":"Lung Cancer Prevention Screening Programme in Italy","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7324,"lead_sponsor_name":"Ugo Pastorino","has_results":false},{"nct_id":"NCT04492384","title":"Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients","phase":"","overall_status":"COMPLETED","enrollment_count":6396,"lead_sponsor_name":"Eurasian Association of Therapists","has_results":false},{"nct_id":"NCT06419400","title":"A Research Study to Explore the Impact of GP Support Via Text Messages to Patients With Asthma and/or COPD","phase":"NA","overall_status":"COMPLETED","enrollment_count":6053,"lead_sponsor_name":"Accurx","has_results":false},{"nct_id":"NCT03131362","title":"Realize the Current Situation of COPD Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":5020,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04318912","title":"An Observational Registry of Chinese COPD Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03899298","title":"Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"R3 Stem Cell","has_results":false},{"nct_id":"NCT06283966","title":"A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03581227","title":"The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)","phase":"","overall_status":"COMPLETED","enrollment_count":4679,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT07359287","title":"Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT01985334","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4389,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06316544","title":"China Elderly Comorbidity Medical Database","phase":"","overall_status":"UNKNOWN","enrollment_count":4100,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT01966107","title":"Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":3635,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06350305","title":"Screening for High-risk Chronic Obstructive Pulmonary Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Henan University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT05226416","title":"Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":3554,"lead_sponsor_name":"Eurasian Association of Therapists","has_results":false},{"nct_id":"NCT03182309","title":"Registry for Chronic Obstructive Pulmonary Disease With Sleep Apnea Hypopnea Syndrome in China","phase":"","overall_status":"UNKNOWN","enrollment_count":3502,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT03251157","title":"Dietary Intake in Adults From the GA2LEN Folow-up Survey","phase":"","overall_status":"COMPLETED","enrollment_count":3500,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT04320342","title":"A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3433,"lead_sponsor_name":"Chiesi Farmaceutici S.p.A.","has_results":false},{"nct_id":"NCT07457073","title":"AI-Powered Sound Analysis for COPD Screening","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT07059273","title":"A COPD Data Registry for Participants With Frequent Exacerbations","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT04709120","title":"Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":2968,"lead_sponsor_name":"Eurasian Association of Therapists","has_results":false},{"nct_id":"NCT07518446","title":"Somatic Health Screening for Adults in Outpatient Psychiatric Care in Denmark (SomaScreen)","phase":"NA","overall_status":"RECRUITING","enrollment_count":2800,"lead_sponsor_name":"Amager Hospital","has_results":false},{"nct_id":"NCT04301505","title":"Improvement in COPD Elderly Patients Health: Study Protocol","phase":"NA","overall_status":"COMPLETED","enrollment_count":2520,"lead_sponsor_name":"Medical University of Lodz","has_results":false},{"nct_id":"NCT01443845","title":"Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2354,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04691752","title":"Management of Patients With Chronic Obstructive Pulmonary Disease in Granada: a Clinical Audit","phase":"","overall_status":"UNKNOWN","enrollment_count":2280,"lead_sponsor_name":"Andalusian School of Public Health","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}